Results 111 to 120 of about 128,993 (222)

Beyond Drugs or Surgery: Precision and Equity in Obesity Care

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Ron T. Varghese   +4 more
wiley   +1 more source

Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development

open access: yesBiologics: Targets & Therapy
Ranjit Ranbhor,1 Priyanka Kulkarni2 1Business Development, Portfolio and Patents, Odin Pharmaceuticals LLC, Somerset, NJ, USA; 2Feliciano School of Business, Montclair State University, Montclair, NJ, USACorrespondence: Ranjit Ranbhor, Business ...
Ranbhor R, Kulkarni P
doaj  

Acknowledgement to Reviewers of Pharmaceuticals in 2017

open access: yes, 2018
Peer review is an essential part in the publication process, ensuring that Pharmaceuticals maintains high quality standards for its published papers[...
Pharmaceuticals Editorial Office
core   +1 more source

Switching from one infliximab biosimilar ({CT}-P13) to another infliximab biosimilar ({SB}2) in patients with chronic plaque psoriasis

open access: yes, 2020
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar ...
C. Virga   +6 more
core   +1 more source

Biosimilar medicines in rheumatology

open access: yes, 2015
Biosimilar medicines are biological medicines that have been developed to be highly similar and clinically equivalent to an existing biological medicine. The introduction of these medicines provides additional patient choice and enables financial savings.
Hawkins, T, Emery, P
core   +1 more source

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

open access: yesClinicoEconomics and Outcomes Research, 2018
Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics ...
Schwartzberg LS   +6 more
doaj  

Impact of biosimilar medicinal products in the EU pharmaceutical market [PDF]

open access: yesClinical Therapeutics, 2015
A. Grozdanova   +5 more
openaire   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study [PDF]

open access: yes
Debdulal Chakraborty,1 Tushar Kanti Sinha,1 Sourav Sinha,2 Rupak Kanti Biswas,2 Aniruddha Maiti,3 Krishnendu Nandi,2 Dinesh Rungta,1 Ranabir Bhattacharya1 1Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, WB, India; 2Vitreo-retina Services ...
Nandi K   +7 more
core  

REGULATORY AND ANALYTICAL SCIENCE OF BIOSIMILARS: A PHARMACEUTICAL CHEMISTRY PERSPECTIVE

open access: yes
The development and approval of biosimilars represent a significant advancement in pharmaceutical science, offering cost-effective therapeutic alternatives to originator biologics. From a pharmaceutical chemistry perspective, the regulatory and analytical evaluation of biosimilars demands a rigorous, multidisciplinary approach to ensure comparable ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy